Waning Immunity after the BNT162b2 Vaccine in Israel

BACKGROUND: In December 2020, Israel began a mass vaccination campaign against coronavirus disease 2019 (Covid-19) by administering the BNT162b2 vaccine, which led to a sharp curtailing of the outbreak. The rate ratio for severe disease among persons fully vaccinated in the month when they were first eligible, as compared with those fully vaccinated in March, was 1.8 among persons 60 years of age or older and 2.2 among those 40 to 59 years of age; owing to small numbers, the rate ratio could not...

⚡ This is an original paraphrased summary — not copied from the abstract. Full paper available at the source link below.

• 1 After a period with almost no cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, a resurgent Covid-19 outbreak began in mid-June 2021.
• 2 Possible reasons for the resurgence were reduced vaccine effectiveness against the delta (B.1.617.2) variant and waning immunity.
• 3 The extent of waning immunity of the vaccine against the delta variant in Israel is unclear.

Understanding this could lead to better treatments, improved diagnostics, or a deeper grasp of how the human body works — benefiting patient care globally.

This summary is based on publicly available metadata and abstract. For the full research paper, visit the original source: